Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...

To generate successful gene therapies that are capable of delivering nucleic acids to specific cells and tissues, scientists must carefully design their products. They can employ either recombinant ...

‍COLUMBUS, Ohio, May 12, 2025 /PRNewswire/ -- Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has ...

Researchers develop a nanosensing platform that can assess the quality of individual viral vector particles Viral vectors hold much potential for gene editing and gene therapy, but there is a pressing ...

With this information in hand, researchers who are developing a gene therapy to treat a muscle condition, for instance, could use the atlas to identify AAV vectors that preferentially target the ...

Viral vectors are critical vehicles for the delivery of life-saving cell and gene therapies. Adeno-associated virus (AAV) and lentiviral vectors (LVV), two of the most widely used vector platforms, ...

Sarepta Therapeutics SRPT announced that the FDA has granted platform-technology designation to its viral vector rAAVrh74, used in the investigational gene therapy SRP-9003. This therapy is being ...

MIP Discovery today announced the Company’s rebrand to Tozaro, completing its transition to becoming a technology innovator in the cell and gene therapy (CGT) bioprocessing sector. The rebrand comes ...

Gene therapy has a reputation as a one-time intervention that has a lifelong effect. It’s an all-or-nothing proposition. But what if it wasn’t? What if gene therapy could be dialed up or down, on a ...

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.